| Literature DB >> 20807400 |
Carola Huthmacher1, Andreas Hoppe, Sascha Bulik, Hermann-Georg Holzhütter.
Abstract
BACKGROUND: Despite enormous efforts to combat malaria the disease still afflicts up to half a billion people each year of which more than one million die. Currently no approved vaccine is available and resistances to antimalarials are widely spread. Hence, new antimalarial drugs are urgently needed.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20807400 PMCID: PMC2941759 DOI: 10.1186/1752-0509-4-120
Source DB: PubMed Journal: BMC Syst Biol ISSN: 1752-0509
Overview of assembled metabolic network for P. falciparum and the human erythrocyte
| Organism | Reactions | Transporters | Metabolites | Genes | Compartments |
|---|---|---|---|---|---|
| Plasmodium falciparum | 998 | 377 | 1622 | 579 | 6 |
| Human erythrocyte | 349 | 88 | 566 | - | 1 |
Figure 1Illustration of presented flux balance approach to predict life cycle specific metabolism. Given the gene expression data (blue table) flux distributions (red arrows) within the shown example metabolic network (blue arrows) can be inferred for time points t1 and t2 as depicted in (A). However, neither flux direction nor flux strength can be deduced from gene expression alone (indicated by question marks next to flux arrows). The set of all possible flux distributions that are consistent with the gene expression data can be reduced by knowledge about target fluxes such as biomass production (i). Reactions that are not supported by genome annotation might represent errors in the network assembly. Therefore it is desirable to prevent the usage of such reactions in calculated flux distributions (ii). An enzyme or a transporter that is able to process different metabolites does not necessarily convert all substrates at same rates. If one reaction product is not converted further by subsequent enzymes, it accumulates and as a consequence the net production rate is close to zero, even if the gene is expressed and substrate is available (iii). The flux solution space can be narrowed down further when assuming that biomass production is achieved with a minimal amount of nutrients (iv), which are of varying availability (v). Gene products can be present within a cell, even when the gene transcript is not detectable, as proteins appear later than the corresponding mRNA and protein degradation might be delayed compared to mRNA degradation. Considering proteins to be present whose transcript was detectable during a previous time point (vi) presumably reflects the actual cellular status better than taking only the current transcription snapshot into account. The flux distribution calculated by our flux balance approach, which incorporates all these issues, is shown in (B).
Figure 2Predicted host parasite metabolite exchanges using improved algorithm. Flux distributions have been predicted with our improved flux balance approach (see Figure 1) for each time point of the intraerythrocytic developmental cycle for which a gene expression profile exists. Simulations were conducted on the basis of the combined metabolic network of parasite and host and additional constraints reflecting knowledge about the blood stage. Furthermore, the expression status of genes during preceding time points was considered for the flux calculations. Resulting metabolite exchanges between host and parasite are depicted in this figure. Red matrix entries represent metabolites that are predicted to be imported into the parasite, while green matrix entries represent metabolites secreted into the host compartment.
Metabolite exchanges between parasite and host: prediction vs. experiment
| Metabolite | Predicted | Experiment | Comment | References |
|---|---|---|---|---|
| Glucose | Uptake | uptake | [ | |
| Lactate | Secretion | secretion | [ | |
| Hemoglobin | uptake | uptake | [ | |
| Amino acids | Secretion | secretion | [ | |
| Isoleucine | uptake | uptake | [ | |
| Nucleosides/nucleobases | uptake | uptake | [ | |
| Choline | uptake | uptake | [ | |
| Ethanolamine | almost no exchange | uptake | No gene assigned to ethanolamine transporter | [ |
| Phosphatidylethanolamine | uptake | uptake | [ | |
| Phosphatidylserine | uptake | uptake | [ | |
| Phosphate | uptake | uptake | [ | |
| Pantothenate | uptake | uptake | [ | |
| Nicotinamide/nicotinate | uptake | uptake | [ | |
| Folate | uptake | uptake | [ | |
| 4-aminobenzoic acid | uptake | uptake | [ | |
| ADP | uptake/secretion | uptake | secretion in early blood stage when ATP can still be salvaged from host | [ |
| ATP | uptake/secretion | secretion | uptake in early blood stage when host glycolysis is not repressed yet | [ |
| Glycerol | uptake/secretion | uptake/secretion | [ | |
| Glutathione conjugate | secretion | secretion | [ | |
| Ornithine | mostly secretion | secretion | [ | |
| Cholesterol | uptake | uptake | [ | |
| Formate | no exchange | secretion | Erythrocyte lacks reactions and transport processes to dispose of metabolite | [ |
| Fe2+ | no exchange/uptake | uptake | [ | |
| H+ | Mostly secretion | secretion | [ | |
| HC03- | no exchange | secretion | Erythrocyte lacks reactions and transport processes to dispose of metabolite | [ |
Gold standard set of essential enzymes
| EC | Reaction | Choke-points | Found by FBA | Comment | Reference |
|---|---|---|---|---|---|
| 1.1.1.205 | IMP dehydrogenase | Yes | No | Precursor import (adenosine, hypoxanthine, inosine) | [ |
| 1.1.1.267 | 1-deoxy-D-xylulose-5-phosphate reducetoisomerase | Yes | Yes | [ | |
| 1.3.1.9 | enoyl-ACP-reductase | Yes | Yes | [ | |
| 1.3.3.1 | Dihydroorotate oxidase | No | Yes | [ | |
| 1.3.99.1 | Succinate dehydrogenase | No | No | Presumably unspecific off-target effects | [ |
| 1.5.1.3 | Dihydrofolate reductase | No | No | Necessary to block all reactions catalyzed by the enzyme | [ |
| 1.6.5.3 | NADH dehydrogenase (ubiquinone) | No | No | Presumably unspecific off-target effects | [ |
| 1.8.1.7 | glutathione reductase | Yes | Yes | [ | |
| 1.8.1.9 | thioredoxin reductase | Yes | Yes | [ | |
| 1.10.2.2 | cytochrome c reductase | Yes | Yes | [ | |
| 1.15.1.1 | superoxide dismutase | Yes | Yes | [ | |
| 1.17.4.1 | Ribonucleoside-diphosphate reductase | No | Yes | [ | |
| 2.1.1.100 | Protein-S-isoprenylcysteine-O-methyltransferase | Yes | Yes | [ | |
| 2.1.1.103 | Phosphoethanolamine methyltrans-ferase | Yes | No | Presumably unspecific off-target effects | [ |
| 2.1.1.45 | Thymidylate synthase | No | Yes | [ | |
| 2.1.1.64 | 3-Demethylubiquinone-9,3-O-methyltransferase | Yes | Yes | [ | |
| 2.3.1.24 | sphingosine-N-acyltransferase | Yes | Yes | [ | |
| 2.3.1.37 | delta-aminolevulinate synthase | Yes | Yes | [ | |
| 2.3.1.41 | 3-Oxoacyl-[acyl-carrier protein] synthase | Yes | Yes | [ | |
| 2.3.1.50 | serine-palmitoyl transferase | No | Yes | [ | |
| 2.4.2.1 | Purine-nucleoside phosphorylase | Yes | No | Precursor import (hypoxanthine, xanthine) | [ |
| 2.4.2.8 | Hypoxanthine phosphoribosyltransferase | Yes | No | Necessary to block all reactions catalyzed by the enzyme | [ |
| 2.5.1.15 | Dihydropteroate synthase | Yes | No | Precursor import (folate) | [ |
| 2.5.1.16 | Spermidine synthase | Yes | No | Precursor import (spermidine) | [ |
| 2.5.1.18 | Glutathione transferase | Yes | Yes | [ | |
| 2.5.1.19 | 3-Phosphoshikimate 1- carboxyvinyltransferase | Yes | No | Precursor import (4-aminobenzoate, folate) | [ |
| 2.5.1.58 | Farnesyl-diphosphate Farnesyltransferase | No | Yes | [ | |
| 2.7.1.32 | Choline kinase | No | No | Presumably unspecific off-target effects | [ |
| 2.7.8.3 | Ceramide-cholinephosphotransferase | Yes | Yes | [ | |
| 3.3.1.1 | S-adenosyl-l-homocysteine hydrolase | Yes | Yes | [ | |
| 3.4.11.1 | leucine aminopeptidase | Yes | No | Precursor import (amino acids) | [ |
| 3.4.14.1 | dipeptidyl aminopeptidase 1 | No | No | Precursor import (amino acids) | [ |
| 3.4.23.38 | plasmepsins (aspartic acid proteases) | No | No | Precursor import (amino acids) | [ |
| 3.4.23.39 | plasmepsins (aspartic acid proteases) | No | No | Precursor import (amino acids) | [ |
| 3.5.1.89 | N-acetyl glucosaminylphosphatidyli-nositol deacetylase | No | Yes | [ | |
| 3.5.2.3 | dihydroorotase | Yes | Yes | [ | |
| 3.5.4.4 | Adenosine deaminase | Yes | No | Precursor import (hypoxanthine, inosine, xanthine) | [ |
| 4.1.1.17 | Ornithine decarboxylase | No | No | Precursor import (spermidine, putrescine); alternative reaction R01152 | [ |
| 4.1.1.23 | Orotidine-5'-phosphate decarboxylase | Yes | Yes | [ | |
| 4.1.1.50 | Adenosylmethionine decarboxylase | No | No | Precursor import (spermidine) | [ |
| 4.1.2.13 | Fructose-bisphosphate aldolase | Yes | No | Presumable main antimalarial effect is impaired host cell invasion | [ |
| 4.2.1.1 | carbonic anhydrase | Yes | Yes | [ | |
| 4.2.1.24 | Delta-aminolevulinic acid dehydratase | No | Yes | [ | |
| 4.2.1.58-61 | 3-hydroxyacyl-ACP dehydratase | Yes | Yes | [ | |
| 4.2.3.5 | Chorismate synthase | Yes | No | Precursor import (4-aminobenzoate, folate) | [ |
| 4.4.1.5 | Lactoylglutathione lyase | Yes | Yes | [ | |
| 4.6.1.12 | 2-C-methyl-D-erythritol-2,4- Cyclodiphosphate-synthase | No | Yes | [ | |
| 5.99.1.2 | topoisomerase I | Yes | Yes | [ | |
| 5.99.1.3 | topoisomerase II | Yes | Yes | [ | |
| 6.1.1.3 | Threonine-tRNA ligase | Yes | Yes | [ | |
| 6.1.1.7 | Alanine-tRNA ligase | Yes | Yes | [ | |
| 6.3.2.2 | Gamma-glutamylcysteine synthetase | Yes | Yes | [ | |
| 6.3.4.4 | Adenylosuccinate synthetase | Yes | Yes | [ | |
| 6.3.5.2 | GMP synthetase | No | No | Necessary to block all reactions catalyzed by the enzyme; precursor import(guanine/guanosine) | [ |
| 6.3.5.5 | Carbamoyl-phosphate synthase (glutamine-hydrolysing) | No | Yes | [ | |
| 6.3.5.8 | amino-deoxychorismate synthase | No | No | Precursor import (4-aminobenzoate, folate) | [ |
| 6.4.1.2 | Acetyl-CoA carboxylase | Yes | Yes | [ |
Figure 3Evaluation of predicted drug targets. We conducted FBA based knock-out simulations to uncover reactions within the metabolic network of the parasite that are essential for the production of metabolites assumed to be important for parasite development (see Additional file9). The predicted set of indispensable reactions, which presumably represent good drug targets, was evaluated on the basis of a gold standard set that contains 57 experimentally verified essential enzymes. We determined true positives (TP), false positives (FP), false negatives (FN), and true negatives (TN) and calculated based on these numbers sensitivity, specificity, accuracy and precision of our method as well as the corresponding enrichment factor (red numbers). To compare our method to a previously proposed method for drug target detection, the choke-point analysis, we additionally identified all choke-points within the parasite's metabolic network and calculated the same statistics (green numbers).
Top ranking predicted essential reactions
| Enzyme name | Compartment | Pathway | EC | Super-Target | Score |
|---|---|---|---|---|---|
| adenylate cyclase | apicoplast | Purine metabolism | 4.6.1.1 | x | 4 |
| fumarase | cytosol | Citrate cycle | 4.2.1.2 | x | 4 |
| 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase | apicoplast | Biosynthesis of isopentenyl diphosphate | 2.7.7.60 | x | 4 |
| 4-hydroxy-3-methylbut-2-enoyl-diphosphate synthase | apicoplast | Biosynthesis of isopentenyl diphosphate | 1.17.4.3 | 3 | |
| CDP-ME kinase | apicoplast | Biosynthesis of isopentenyl diphosphate | 2.7.1.148 | 3 | |
| pantetheine-phosphate adenylyltransferase | cytosol | CoA biosynthesis | 2.7.7.3 | 3 | |
| pyridoxal 5-phosphate synthase | cytosol | Vitamin B6 metabolism | 3 | ||
| amino acid transporter | Cytosol ↔ apicoplast | Transport | 3 | ||
| geranyl-diphosphate synthase | cytosol | Terpenoid biosynthesis | 2.5.1.1 | x | 2 |
| farnesyl-diphosphate synthase | cytosol | Terpenoid biosynthesis | 2.5.1.10 | x | 2 |
| 2-Octaprenylphenol hydroxylase | mitochondrion | Ubiquinone biosynthesis | 1.14.13.- | x | 2 |
| ubiquinone biosynthesis methyltransferase | mitochondrion | Ubiquinone biosynthesis | 2.1.1.- | x | 2 |
| uroporphyrinogen decarboxylase | apicoplast | Porphyrin metabolism | 4.1.1.37 | x | 2 |
| coproporphyrinogen oxidase | apicoplast | Porphyrin metabolism | 1.3.3.3 | x | 2 |
| UMP-CMP kinase | apicoplast | Pyrimidine metabolism | 2.7.4.14 | x | 2 |
| aspartate carbamoyltransferase | cytosol | Pyrimidine metabolism | 2.1.3.2 | x | 2 |
| orotate phosphoribosyltransferase | cytosol | Pyrimidine metabolism | 2.4.2.10 | x | 2 |
| cysteine desulfurase | apicoplast/mitochondrion | Fe-S-protein biogenesis | 2.8.1.7 | x | 2 |
| tRNA ligase (Ile, Lys, Met, Trp, Tyr) | cytosol/apicoplast/mitochondrion | Aminoacyl-tRNA biosynthesis | 6.1.1.1/6.1.1.2/6.1.1.5/6.1.1.6/6.1.1.10 | x | 2 |
| glutathione synthase | cytosol | Glutathione metabolism | 6.3.2.3 | x | 2 |
| riboflavin kinase | cytosol | Riboflavin metabolism | 2.7.1.26 | x | 2 |
| glucosamine 6-phosphate synthase | apicoplast | Aminosugars metabolism | 2.6.1.16 | x | 2 |
| mannose-6-phosphate isomerase | cytosol | Fructose and mannose metabolism | 5.3.1.8 | x | 2 |
| cytochrome-c oxidase | mitochondrion | Oxidative phosphorylation | 1.9.3.1 | x | 2 |
| choline-phosphate cytidylyltransferase | cytosol | Glycerophospholipid metabolism | 2.7.7.15 | x | 2 |
| deoxyhypusine synthase | cytosol | Activation of eiF5A | 2.5.1.46 | x | 2 |